SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
Open Access
- 10 February 2023
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 102 (6), e32795
- https://doi.org/10.1097/md.0000000000032795
Abstract
Coronavirus disease 2019 (COVID-19) is a major global health concern. In contrast to adults, the course of the disease has been observed to be mild or even asymptomatic in children. It is therefore both clinically and epidemiologically important to measure the seroprevalence in children and adolescents to discern the overall morbidity of the disease and to compare these findings with similar data collected globally. We conducted a cross-sectional study between March and July of 2022 at the Children Clinical University Hospital in Riga, Latvia, to evaluate the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Participants aged 0 to 18 years were enrolled during hospitalization for reasons other than COVID-19. The levels of SARS-CoV-2 spike protein and nucleocapsid antibodies were measured in blood samples. The possibility of transplacental antibody transport was evaluated by directly interviewing the mothers of participants aged 18 months and younger. Various demographic and epidemiological risk factors and their association with seroprevalence were analyzed. Positive SARS-CoV-2 nucleocapsid antibodies were designated the main criterion for seropositivity. Of 200 enrolled children, 173 were found to be seropositive, resulting in an overall seroprevalence of 86.5%. The highest seroprevalence was detected in children and adolescents aged 12 to 18 years. With the progression of the COVID-19 pandemic, the seroprevalence in children has increased significantly. We found that almost 1-third of seropositive children in our study population were unaware of being previously infected with SARS-CoV-2 due to an asymptomatic course of the disease. Our study findings pertaining to high seropositivity among children and adolescents might be beneficial for public authorities to adapt epidemiological strategies and prevention measures. The high seroprevalence rate reported here and in many other populations around the world suggests that COVID-19 will likely become one of the many seasonal viral infections.Keywords
This publication has 9 references indexed in Scilit:
- The Seroprevalence of SARS-CoV-2 IgG Antibodies in Children Hospitalized for Reasons Other Than COVID-19Journal of Clinical Medicine, 2022
- Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021Nature Communications, 2022
- Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022Morbidity and Mortality Weekly Report (MMWR), 2022
- Europe must come together to confront omicronBMJ, 2022
- A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United StatesPLOS ONE, 2021
- Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccineJCI Insight, 2021
- Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysisArchives of Disease in Childhood, 2021
- Children and Adolescents With SARS-CoV-2 InfectionThe Pediatric Infectious Disease Journal, 2020
- Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research NetworksEuropean Journal of Pediatrics, 2020